Frontlight ResearchEarly access
WithdrawnPhase 2
18-fluorofuranylnorprogesterone (FFNP) PET/MRI as a Potential Biomarker of Response to Progesterone Therapy
Key facts
- Who runs it
- UNC Lineberger Comprehensive Cancer Center
- Trial code
- Status
- Withdrawn
- Phase
- Phase 2
- Started
- 15 Feb 2024
- Expected to end
- Dec 2027
- Type of study
- Interventional
- Treatments tested
- 18F-fluorofuranylnorprogesterone PET / MRI
- Record updated
- 14 October 2025
- Why it stopped
- Drug cannot be produced and scanner down.
Who can take part
- Age
- 18 years and older
- Sex
- Women only
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Female age 18 or older
- Histologically confirmed CAH or Grade 1 EC
- No prior surgical or hormonal treatment for CAH or Grade 1 EC
- Planned treatment with levonorgestrel-releasing intrauterine device (LR-IUD) for CAH or grade 1 EC
Who cannot take part
- Prior hormone treatment for breast cancer
- Known hypersensitivity to gadolinium or FFNP or to any component of gadolinium or FFNP refractory to standard medications (antihistamines, steroids)
- Impaired kidney function (serum creatinine level > 1.8 mg/dl or a glomerular filtration rate < 60 as approximated using serum creatinine levels) unless anuric and on dialysis
- Inability to complete PET/MR scans due to severe claustrophobia
- Institutionalized subject (prisoner or nursing home subject)
- Implanted metallic devices, parts, vascular clips, or other foreign bodies
- Any woman who is pregnant or has reason to believe she is pregnant (the possibility of pregnancy has to be excluded by negative urine (β-HCG) results, obtained within 24 hours before FFNP administration, or on the basis of patient history)
About the trial
What the trial wants to find out
Purpose: The purpose of this study is to evaluate FFNP PET/MRI's utility for predicting response to Levonorgestrel-releasing Intrauterine Device (LR-IUD) hormonal therapy for Complex Atypical hyperplasia (CAH) and Endometrial Cancer (EC).
Read full original descriptionShow less
Participants: Eight women with histologically confirmed CAH or Grade 1 EC who have planned treatment with LR-IUD will be recruited..
Procedures (methods): The is a prospective, single arm, pilot study of 8 participants who will receive one FFNP PET/MRI scan. Medical records will be followed for 6 months.
The group in the trial
- 18F-fluorofuranylnorprogesterone PET / MRITreatment being tested
All enrolled subjects will receive the tracer and then have a PET/MRI scan.
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- 18-fluorofuranylnorprogesterone (FFNP) Positron Emission Tomography-Magnetic Resonance Imaging (PET/MRI) as a Potential Biomarker of Response to Progesterone Therapy in Complex Atypical Hyperplasia (CAH) and Grade 1 Endometrial Cancer (EC)
- Record updated
- 14 October 2025